Viatris' sNDA for MR-141 Accepted by FDA with PDUFA Date Set
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy VTRS?
Source: PRnewswire
Viatris Inc. shares rose by 5.02% as the stock crossed above its 5-day SMA, reflecting positive investor sentiment.
The FDA has accepted Viatris' supplemental New Drug Application (sNDA) for MR-141, a treatment for presbyopia, with a PDUFA goal date set for October 17, 2026. This acceptance is supported by positive Phase 3 trial data, enhancing market confidence in the drug's potential. Additionally, Viatris has entered a global licensing agreement with Opus Genetics for exclusive commercialization rights in the U.S., further solidifying its market position.
This FDA acceptance marks a significant milestone for Viatris, positioning MR-141 as a promising treatment option in a market with substantial demand. The company's strategic moves in R&D and licensing agreements are likely to bolster its competitive edge in the ophthalmic drug sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to fall
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 14.930
Low
10.00
Averages
13.25
High
16.00
Current: 14.930
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viatris Named Among Best Dividend Stocks for March
- Price Target Increase: UBS raised Viatris's price target from $18 to $20 while maintaining a Buy rating, indicating improvements in cost savings and growth outlook, despite a 5% drop in shares following earlier gains.
- Strong Financial Performance: Viatris reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion for 2025, demonstrating solid positioning for sustainable long-term growth, with the CEO highlighting 2026 as a pivotal growth year.
- Significant R&D Progress: The company achieved positive results in five Phase III studies, with key program enrollments progressing well and expected to complete by 2026, laying the groundwork for future product line expansions.
- Shareholder Returns and Cost Savings: Viatris returned over $1 billion to shareholders through dividends and share repurchases in the past year, while also anticipating $650 million in gross cost savings over three years, with a portion earmarked for growth investments.
See More
Bastion Asset Management Acquires Stake in Parsons
- New Investment Position: Bastion Asset Management disclosed a new position in Parsons by acquiring 128,186 shares in Q4 2025, with an estimated transaction value of $8.04 million, indicating a strategic focus on defense and infrastructure sectors.
- Significant Holding Proportion: Following this transaction, Parsons represents 4.44% of Bastion's $181.13 million reportable U.S. equity assets, highlighting its importance in the portfolio and the firm's preference for stable cash flow investments.
- Market Performance Analysis: As of February 5, 2026, Parsons shares were priced at $67.52, reflecting a 13% decline over the past year and underperforming the S&P 500 by 25.12 percentage points, suggesting market caution regarding its future growth prospects.
- Diversified Business Advantage: Parsons operates a dual-segment model in defense and infrastructure, ensuring that when defense spending contracts, infrastructure projects can compensate for revenue shortfalls, demonstrating resilience amid economic fluctuations.
See More
Bastion Asset Management Acquires $8M Stake in Parsons
- New Position Disclosure: On February 6, 2026, Bastion Asset Management disclosed a new position in Parsons (NYSE:PSN), acquiring 128,186 shares valued at approximately $8.04 million, indicating a strategic interest in defense and infrastructure sectors.
- Holding Proportion Analysis: Following this transaction, Parsons represents 4.44% of Bastion's portfolio, which totaled $181.13 million in reportable U.S. equity assets as of December 31, 2025, reflecting Bastion's preference for stable income investments.
- Market Performance Overview: As of February 5, 2026, Parsons shares were priced at $67.52, down 13% year-over-year, underperforming the S&P 500 by 25.12 percentage points, indicating market caution regarding its future growth prospects.
- Business Diversification: Parsons generates revenue from various sectors, particularly through contracts with the Pentagon, demonstrating its ability to maintain stable cash flow amidst economic fluctuations, making it suitable for investors seeking steady returns.
See More
AI Stocks Are Declining While Others Surge: 6 Buy-Worthy Stocks to Consider.
Market Reaction: An online memo has reportedly contributed to a decline in the U.S. stock market, suggesting a bleak economic outlook.
Impact of AI: The memo warns that artificial intelligence could lead to significant job losses in white-collar sectors, resulting in a series of economic crises including stock crashes and falling housing values.
See More
Viatris Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Viatris reported total revenues of $14.3 billion and adjusted EBITDA of $4.2 billion for 2025, demonstrating robust execution across its diversified global business, with an expected 2% growth in revenue and EBITDA in 2026.
- Shareholder Returns and Acquisitions: The company returned over $1 billion to shareholders through dividends and share repurchases in 2025 and completed 60 regional transactions, including the acquisition of Aculys Pharma in Japan, enhancing its market competitiveness.
- R&D Progress and Strategic Goals: Viatris achieved five positive Phase III clinical trial results in 2025 and plans to secure eight regulatory approvals in 2026, showcasing strong advancement in its innovative product pipeline.
- Cost Savings Initiative: The company anticipates approximately $650 million in gross cost savings over three years, with plans to reinvest $250 million into growth initiatives, aiming to support sustainable growth through operational optimization.
See More
Viatris Stock Declines 1.4% Following Fourth Quarter Earnings Report
- Company Performance: Viasat shares fell by 1.4% following the release of their Q4 results.
- Market Reaction: The decline in share price indicates investor response to the company's financial performance.
- Financial Overview: The Q4 results may have included key metrics that influenced market sentiment.
- Future Outlook: Analysts and investors will likely be assessing the implications of these results on Viasat's future performance.
See More
Viatris Named Among Best Dividend Stocks for March
- Price Target Increase: UBS raised Viatris's price target from $18 to $20 while maintaining a Buy rating, indicating improvements in cost savings and growth outlook, despite a 5% drop in shares following earlier gains.
- Strong Financial Performance: Viatris reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion for 2025, demonstrating solid positioning for sustainable long-term growth, with the CEO highlighting 2026 as a pivotal growth year.
- Significant R&D Progress: The company achieved positive results in five Phase III studies, with key program enrollments progressing well and expected to complete by 2026, laying the groundwork for future product line expansions.
- Shareholder Returns and Cost Savings: Viatris returned over $1 billion to shareholders through dividends and share repurchases in the past year, while also anticipating $650 million in gross cost savings over three years, with a portion earmarked for growth investments.
See More
Bastion Asset Management Acquires Stake in Parsons
- New Investment Position: Bastion Asset Management disclosed a new position in Parsons by acquiring 128,186 shares in Q4 2025, with an estimated transaction value of $8.04 million, indicating a strategic focus on defense and infrastructure sectors.
- Significant Holding Proportion: Following this transaction, Parsons represents 4.44% of Bastion's $181.13 million reportable U.S. equity assets, highlighting its importance in the portfolio and the firm's preference for stable cash flow investments.
- Market Performance Analysis: As of February 5, 2026, Parsons shares were priced at $67.52, reflecting a 13% decline over the past year and underperforming the S&P 500 by 25.12 percentage points, suggesting market caution regarding its future growth prospects.
- Diversified Business Advantage: Parsons operates a dual-segment model in defense and infrastructure, ensuring that when defense spending contracts, infrastructure projects can compensate for revenue shortfalls, demonstrating resilience amid economic fluctuations.
See More
Bastion Asset Management Acquires $8M Stake in Parsons
- New Position Disclosure: On February 6, 2026, Bastion Asset Management disclosed a new position in Parsons (NYSE:PSN), acquiring 128,186 shares valued at approximately $8.04 million, indicating a strategic interest in defense and infrastructure sectors.
- Holding Proportion Analysis: Following this transaction, Parsons represents 4.44% of Bastion's portfolio, which totaled $181.13 million in reportable U.S. equity assets as of December 31, 2025, reflecting Bastion's preference for stable income investments.
- Market Performance Overview: As of February 5, 2026, Parsons shares were priced at $67.52, down 13% year-over-year, underperforming the S&P 500 by 25.12 percentage points, indicating market caution regarding its future growth prospects.
- Business Diversification: Parsons generates revenue from various sectors, particularly through contracts with the Pentagon, demonstrating its ability to maintain stable cash flow amidst economic fluctuations, making it suitable for investors seeking steady returns.
See More
AI Stocks Are Declining While Others Surge: 6 Buy-Worthy Stocks to Consider.
Market Reaction: An online memo has reportedly contributed to a decline in the U.S. stock market, suggesting a bleak economic outlook.
Impact of AI: The memo warns that artificial intelligence could lead to significant job losses in white-collar sectors, resulting in a series of economic crises including stock crashes and falling housing values.
See More
Viatris Q4 2025 Earnings Call Highlights
- Strong Financial Performance: Viatris reported total revenues of $14.3 billion and adjusted EBITDA of $4.2 billion for 2025, demonstrating robust execution across its diversified global business, with an expected 2% growth in revenue and EBITDA in 2026.
- Shareholder Returns and Acquisitions: The company returned over $1 billion to shareholders through dividends and share repurchases in 2025 and completed 60 regional transactions, including the acquisition of Aculys Pharma in Japan, enhancing its market competitiveness.
- R&D Progress and Strategic Goals: Viatris achieved five positive Phase III clinical trial results in 2025 and plans to secure eight regulatory approvals in 2026, showcasing strong advancement in its innovative product pipeline.
- Cost Savings Initiative: The company anticipates approximately $650 million in gross cost savings over three years, with plans to reinvest $250 million into growth initiatives, aiming to support sustainable growth through operational optimization.
See More
Viatris Stock Declines 1.4% Following Fourth Quarter Earnings Report
- Company Performance: Viasat shares fell by 1.4% following the release of their Q4 results.
- Market Reaction: The decline in share price indicates investor response to the company's financial performance.
- Financial Overview: The Q4 results may have included key metrics that influenced market sentiment.
- Future Outlook: Analysts and investors will likely be assessing the implications of these results on Viasat's future performance.
See More
